Pasithea Therapeutics Announced Safety, Tolerability, Pharmacokinetic And Preliminary Efficacy Data From The First 2 Cohorts Of Patients In Its Phase 1 Clinical Trial Of PAS-004
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics reported positive safety, tolerability, and preliminary efficacy data from its Phase 1 trial of PAS-004. A patient with stage 3 colon cancer showed stable disease with no adverse events, supporting the drug's potential as a MEK inhibitor.
September 26, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics' Phase 1 trial of PAS-004 shows promising safety and efficacy data, with a colon cancer patient achieving stable disease and no adverse events reported.
The positive safety and efficacy data from the Phase 1 trial of PAS-004, especially the stable disease in a colon cancer patient, is likely to boost investor confidence in Pasithea Therapeutics. The absence of adverse events and the drug's potential as a MEK inhibitor for various conditions could positively impact KTTA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100